EBS logo

Emergent BioSolutions (EBS) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

15 November 2006

Indexes:

Not included

Description:

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on creating specialized products and solutions to ensure readiness and response to accidental, intentional, and natural threats to public health. The company was founded in 1998. Emergent's activities are focused on innovative products to ensure readiness and response in six distinct categories of public health threats: chemical, biological, radiological, nuclear hazards; infectious diseases; health on the go; emerging healthcare crises, emergency care, as well as contract development and manufacturing.

Events Calendar

Earnings

Next earnings date:

Mar 06, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Mar 06, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

30 Dec '24 HC Wainwright & Co.
Buy
07 Nov '24 Benchmark
Buy
13 Sept '24 Rodman & Renshaw
Buy
22 Aug '24 Rodman & Renshaw
Buy
16 Aug '24 Benchmark
Buy
09 Aug '24 Benchmark
Buy
03 July '24 Benchmark
Buy
02 July '24 Benchmark
Buy
24 June '24 Benchmark
Buy
21 June '24 Benchmark
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Why Emergent BioSolutions Stock Blasted Higher Today
Why Emergent BioSolutions Stock Blasted Higher Today
Why Emergent BioSolutions Stock Blasted Higher Today
EBS
Motley Fool30 December 2024

An analyst started following Emergent BioSolutions (NYSE: EBS) stock as the final trading week of 2024 began, and investors responded favorably. H.C. Wainwright's Raghuram Selvaraju is now monitoring Emergent, which has a broad range of revenue sources. Selvaraju suggests that Emergent is well-diversified and operates in various medical areas with strong growth potential.

Why Emergent BioSolutions Stock Blasted Higher Today
Why Emergent BioSolutions Stock Blasted Higher Today
Why Emergent BioSolutions Stock Blasted Higher Today
EBS
fool.com30 December 2024

An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.

Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
EBS
zacks.com27 December 2024

The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.

Why Emergent BioSciences Stock Plummeted Today
Why Emergent BioSciences Stock Plummeted Today
Why Emergent BioSciences Stock Plummeted Today
EBS
Motley Fool03 December 2024

Emergent BioSolutions (NYSE: EBS) experienced a drop in its stock price on Tuesday following reports of a share sell-off. The sellers are primarily linked to OHA Agency, which gave Emergent a $250 million loan in August. Emergent clarified in its statement that it will not benefit financially from these sales, as it is not involved in the selling process.

Why Emergent BioSciences Stock Plummeted Today
Why Emergent BioSciences Stock Plummeted Today
Why Emergent BioSciences Stock Plummeted Today
EBS
fool.com03 December 2024

Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities.

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
EBS
seekingalpha.com08 November 2024

Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats.

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
EBS
zacks.com06 November 2024

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago.

BlueOne Card Inc., Announces Definitive Agreement to Acquire Millennium EBS, Inc. in a $12 Million Deal
BlueOne Card Inc., Announces Definitive Agreement to Acquire Millennium EBS, Inc. in a $12 Million Deal
BlueOne Card Inc., Announces Definitive Agreement to Acquire Millennium EBS, Inc. in a $12 Million Deal
EBS
globenewswire.com25 October 2024

BlueOne Card, Inc.(OTCQX: BCRD) a leading fintech provider of payment hub solutions and prepaid cards, announes an agreement to acquire Milennium EBS, Inc.

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
EBS
globenewswire.com25 October 2024

GREENBELT, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Maryland has approved the following announcement of a proposed class action settlement that would benefit purchasers of Emergent BioSolutions Inc. common stock (NYSE: EBS):

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
EBS
globenewswire.com23 October 2024

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024.

FAQ

  • What is the primary business of Emergent BioSolutions?
  • What is the ticker symbol for Emergent BioSolutions?
  • Does Emergent BioSolutions pay dividends?
  • What sector is Emergent BioSolutions in?
  • What industry is Emergent BioSolutions in?
  • What country is Emergent BioSolutions based in?
  • When did Emergent BioSolutions go public?
  • Is Emergent BioSolutions in the S&P 500?
  • Is Emergent BioSolutions in the NASDAQ 100?
  • Is Emergent BioSolutions in the Dow Jones?
  • When was Emergent BioSolutions's last earnings report?
  • When does Emergent BioSolutions report earnings?
  • Should I buy Emergent BioSolutions stock now?

What is the primary business of Emergent BioSolutions?

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on creating specialized products and solutions to ensure readiness and response to accidental, intentional, and natural threats to public health. The company was founded in 1998. Emergent's activities are focused on innovative products to ensure readiness and response in six distinct categories of public health threats: chemical, biological, radiological, nuclear hazards; infectious diseases; health on the go; emerging healthcare crises, emergency care, as well as contract development and manufacturing.

What is the ticker symbol for Emergent BioSolutions?

The ticker symbol for Emergent BioSolutions is NYSE:EBS

Does Emergent BioSolutions pay dividends?

No, Emergent BioSolutions does not pay dividends

What sector is Emergent BioSolutions in?

Emergent BioSolutions is in the Healthcare sector

What industry is Emergent BioSolutions in?

Emergent BioSolutions is in the Drug Manufacturers - Specialty & Generic industry

What country is Emergent BioSolutions based in?

Emergent BioSolutions is headquartered in United States

When did Emergent BioSolutions go public?

Emergent BioSolutions's initial public offering (IPO) was on 15 November 2006

Is Emergent BioSolutions in the S&P 500?

No, Emergent BioSolutions is not included in the S&P 500 index

Is Emergent BioSolutions in the NASDAQ 100?

No, Emergent BioSolutions is not included in the NASDAQ 100 index

Is Emergent BioSolutions in the Dow Jones?

No, Emergent BioSolutions is not included in the Dow Jones index

When was Emergent BioSolutions's last earnings report?

Emergent BioSolutions's most recent earnings report was on 6 November 2024

When does Emergent BioSolutions report earnings?

The next expected earnings date for Emergent BioSolutions is 6 March 2025

Should I buy Emergent BioSolutions stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions